DexCom, Inc. (NASDAQ:DXCM) Shares Bought by MIG Capital LLC

MIG Capital LLC increased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 51.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 859,627 shares of the medical device company’s stock after acquiring an additional 292,127 shares during the period. DexCom accounts for about 7.0% of MIG Capital LLC’s holdings, making the stock its 6th largest position. MIG Capital LLC’s holdings in DexCom were worth $57,629,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. Jennison Associates LLC grew its holdings in DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock valued at $464,782,000 after purchasing an additional 6,544,102 shares during the last quarter. Legal & General Group Plc boosted its holdings in shares of DexCom by 1.7% during the 2nd quarter. Legal & General Group Plc now owns 2,993,049 shares of the medical device company’s stock worth $339,352,000 after buying an additional 49,076 shares during the period. Westfield Capital Management Co. LP grew its stake in DexCom by 44.6% in the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in DexCom by 11.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,734,155 shares of the medical device company’s stock worth $183,298,000 after acquiring an additional 288,381 shares during the period. Finally, Massachusetts Financial Services Co. MA lifted its position in DexCom by 16.9% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after acquiring an additional 353,019 shares during the last quarter. 97.75% of the stock is owned by institutional investors.

Insider Transactions at DexCom

In other DexCom news, EVP Sadie Stern sold 4,259 shares of DexCom stock in a transaction that occurred on Wednesday, November 20th. The shares were sold at an average price of $74.73, for a total value of $318,275.07. Following the transaction, the executive vice president now owns 71,192 shares of the company’s stock, valued at approximately $5,320,178.16. The trade was a 5.64 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $51,585.90. Following the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. This represents a 0.28 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 5,431 shares of company stock valued at $399,319 over the last three months. 0.30% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on DXCM shares. Stifel Nicolaus increased their target price on DexCom from $90.00 to $100.00 and gave the company a “buy” rating in a research note on Friday, August 23rd. StockNews.com cut DexCom from a “buy” rating to a “hold” rating in a research report on Saturday, November 2nd. Robert W. Baird raised their price objective on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Oppenheimer reduced their price target on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating for the company in a report on Friday, October 25th. Finally, Royal Bank of Canada dropped their price objective on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating on the stock in a report on Friday, October 25th. Seven analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $104.59.

DexCom Stock Performance

Shares of NASDAQ:DXCM opened at $78.10 on Thursday. The company has a market capitalization of $30.51 billion, a price-to-earnings ratio of 46.77, a P/E/G ratio of 2.38 and a beta of 1.17. The firm’s 50 day simple moving average is $71.11 and its 200 day simple moving average is $88.51. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a fifty-two week low of $62.34 and a fifty-two week high of $142.00.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.